Is Brief Psychoanalytic Therapy distinctive? A research study

2016 ◽  
pp. 125-138
Author(s):  
R. Peter Hobson
Keyword(s):  
Therapeutic Approach ◽  
Research Study ◽  
Therapeutic Interventions ◽  
Interpersonal Therapy ◽  
Psychoanalytic Therapy ◽  
Formal Study

This chapter describes a formal study of therapeutic interventions in Brief Psychoanalytic Therapy (BPT). The aim of the study was to examine whether the therapeutic approach has distinctive qualities when compared with another relationship-oriented treatment, Interpersonal Therapy (IPT). The materials studied were transcripts from seven sessions of BPT and seven sessions of IPT, each involving different patients and different therapists. Separate therapists “blind” to treatment were asked to rate the transcripts for characteristics captured on a series of adherence scales, including BPT and IPT Adherence Scales. The results indicated very substantial differences between the treatments, with BPT more “interpretive” and IPT more “supportive” in nature.

Brief Psychoanalytic Therapy

2016 ◽  
Author(s):  
R. Peter Hobson
Keyword(s):  
Therapeutic Relationship ◽  
Research Study ◽  
Detailed Examination ◽  
Emotional States ◽  
Case Histories ◽  
Interpersonal Therapy ◽  
Psychoanalytic Therapy ◽  
Psychoanalytic Treatment ◽  
Transference And Countertransference

This book outlines the principles and practice of Brief Psychoanalytic Therapy. An introductory chapter distills those aspects of psychoanalysis that provide a basis for the approach. Special attention is given to how a therapist may promote a patient’s development by registering and containing emotional states that the patient is unable to manage alone. This is followed by an overview of themes and variations in six forms of brief psychodynamic therapy. The remainder of the book is concerned less with theory than with clinical practice. Treatment and Adherence Manuals detail the specifics of therapist orientation and technique, and a formal research study comparing the approach with Interpersonal Therapy is reported. Case histories of individual treatments unfolding over time are complemented by detailed examination of short sequences of patient–therapist dialogue from transcribed sessions. What emerges is a picture of a psychoanalytic treatment that, while brief, is disciplined and coherent in its concentrated focus on analyzing the transference and countertransference in the therapeutic relationship.

PrecisionPanc, Personalised treament for pancreatic cancer, Wellcome Trust

Impact ◽  
2018 ◽  
Vol 2018 (3) ◽  
pp. 6-10
Author(s):  
Andrew Biankin
Keyword(s):  
Pancreatic Cancer ◽  
Translational Research ◽  
Cancer Patients ◽  
Patient Outcomes ◽  
Therapeutic Approach ◽  
Research Study ◽  
Therapeutic Option ◽  
Reliable Information ◽  
Wide Range ◽  
Experienced Team

Simply put, we want to help pancreatic cancer patients, and their doctors, to find and understand accurate and reliable information about that specific patient's cancer that could help them to decide what the most suitable type of treatment is. Our latest research study, which was co-led by Professor Andrew Biankin and was recently published in Nature, demonstrates that pancreatic cancer can be classified into four subtypes - each of which may require a different therapeutic approach. This shows that understanding the molecular differences between the pancreatic cancer in one patient and another is vital when considering what the most suitable therapeutic option is. We also carry out a wide range of basic and translational research studies to help us generally improve our understanding of how pancreatic cancer behaves and grows. Over the coming weeks we will post more details of our projects so you can follow our activities and understand how we are working actively to fight pancreatic cancer. Currently, we are implementing our strategies and thoroughly testing our pipelines and processes to allow us to help patients. Our experienced team of clinicians, researchers, bioinformaticians and lab staff work tirelessly with one thing in mind: improving patient outcomes.

When Therapy Fails

2020 ◽  
pp. 77-94
Author(s):  
Jeffrey A. Kottler ◽  
Richard S. Balkin
Keyword(s):  
Therapeutic Approach ◽  
Therapeutic Interventions ◽  
Contributing Factors

In When Therapy Fails the authors highlight that therapy efforts rarely fail in the sense that clients don’t receive anything meaningful and helpful after their investment of time, effort, and resources. Sometimes clients do not get everything they want from the experience, but it is relatively rare that they leave worse off than when they came. Overall, clients tend to be satisfied with the care they receive and the outcomes associated with it. However, when clients do experience failure in therapy, it is often perceived as the failure of the client, not the failure of the therapist or the therapeutic approach. Numerous therapeutic interventions have been deemed ineffective after years of implementation. Moreover, therapists need to be open to failure with clients and understanding the contributing factors to client failure.

Themes and variations in brief psychodynamic psychotherapy

2016 ◽  
pp. 15-36
Author(s):  
R. Peter Hobson
Keyword(s):  
Mechanisms Of Change ◽  
Substantial Evidence ◽  
Interpersonal Therapy ◽  
Dynamic Psychotherapy ◽  
Psychoanalytic Therapy ◽  
Therapeutic Dialogue ◽  
Principles Of Treatment ◽  
Analytic Therapy ◽  
Cognitive Analytic Therapy ◽  
Psychodynamic Psychotherapies

This chapter surveys a range of relationship-orientated brief therapies: Interpersonal Therapy (IPT), Cognitive-Analytic Therapy (CAT), Dynamic Interpersonal Therapy (DIT), Intensive Short-Term Dynamic Psychotherapy (ISTDP), the Conversational Model (a version of which became known as Psychodynamic Interpersonal Therapy, or PIT), and Brief Psychoanalytic Therapy (BPT). Principles of treatment and mechanisms of change are considered, and for each approach, an excerpt of therapeutic dialogue provides vivid illustration. This establishes a basis for considering how far the treatments have features in common, and how far they are distinctive from one another. The chapter concludes by noting substantial evidence for the effectiveness of brief psychodynamic psychotherapies.

scholarly journals Anemia sideropenica in età pediatrica: pillole di… ferro

QUADERNI ACP ◽  
2021 ◽  
Vol 28 (4) ◽  
pp. 173
Author(s):  
Carla Moscheo ◽  
Elisa Fenizia ◽  
Mariaclaudia Meli ◽  
Giovanna Russo
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Therapeutic Approach ◽  
Therapeutic Interventions ◽  
Deficiency Anemia ◽  
Pediatric Age ◽  
Adequate Intake ◽  
Nosological Entity ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy

Iron deficiency anemia is the most frequent haematological disorder in children. Although much is already known about the diagnostic-therapeutic approach, new frontiers regarding its diagnosis and therapeutic options emerge every day. An adequate intake with the diet is essential and can also be obtained in compliance with vegetarian-type diets. The use of glycinate or lysosomal preparations could positively affect the efficacy of therapy reducing the side effects associated with commonly used iron preparations. Parenteral iron therapy in pediatric age, which is currently limited to selected conditions, may evolve further, as a consequence of the production of molecules such as ferrocarboxymaltose, the use of which is not currently permitted under the age of 14. Further studies are therefore necessary in order to implement the knowledge and diagnostic-therapeutic interventions related to this widespread nosological entity.

Evaluation of Pain and Distress and Therapeutic Interventions for Rectal Prolapse in Mice to Reduce Early Study Removal

2021 ◽  
Author(s):  
Cara M Mitchell ◽  
Gregory W Salyards ◽  
Betty R Theriault ◽  
George P Langan ◽  
Kerith R Luchins
Keyword(s):  
Rectal Prolapse ◽  
Research Study ◽  
Treatment Options ◽  
Therapeutic Interventions ◽  
Study Endpoint ◽  
Petroleum Jelly ◽  
Ongoing Research ◽  
Treatment Groups ◽  
Animal Number ◽  
Pathogen Testing

Rectal prolapse (RP) is a common clinical condition in mice, that does not have a recognized or documented standard ofcare. At our institution, an average of 240 mice develop RP each year. Our practice has been to recommend euthanasia uponidentifying a RP based on its appearance as a painful or distressful condition. This study aimed to assess treatment options that would maintain the RP mucosa and allow mice to reach their study endpoint, and to evaluate the perception of this condition as a painful or distressful event. This study used 120 mice with spontaneous RP, concurrently assigned to ongoing research protocols. Mice were randomly assigned to 1 of 3 treatment groups: petroleum jelly, lidocaine jelly, or no treatment. Fecal samples were collected for pathogen testing, and all mice received an initial base score, followed by weekly blind scores. Upon euthanasia, RP tissue was collected for histopathology. Of the 120 mice identified with RP, 47 mice were breeders; 28% successfully produced 22 additional litters after developing RP. Seventy-three were nonbreeders, with 92% reaching their research study endpoint. No statistically significant differences were detected between the 3 treatment groups based on gross mucosal health, pain and distress, or histopathology. In this study, none of the mice in any group were euthanized based on the RP endpoint scoring criteria. These findings demonstrate that treatment is unnecessary for RP, and mice with RP did not show signs of pain or distress. In adherence to the 3Rs, this study supports animal number reduction and clinical refinement, allowing mice with RPs to reach their intended research study endpoints or produce additional litters.

Burning mouth syndrome: a review of therapeutic approach

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Tahereh Nosratzehi
Keyword(s):  
Therapeutic Approach ◽  
Botulinum Toxin A ◽  
Burning Mouth Syndrome ◽  
Therapeutic Interventions ◽  
Cochrane Library ◽  
Pharmacological Treatments ◽  
Therapeutic Approaches ◽  
Wide Range ◽  
Detailed Assessment ◽  
Burning Mouth

Abstract Burning mouth syndrome (BMS) is described by an intense burning sensation of the tongue or other oral areas without a clear etiopathology. The diagnosis of BMS is challenging due to variations of manifestations. The management of BMS is complicated due to the complex etiology of the disease. Many medications and treatment methods have been recommended for BMS management, but no one confirmed as the standard method. In this study, the therapeutic approaches of BMS were evaluated. The data of the article was obtained from PubMed/MEDLINE, Cochrane Library, and Web of Science. The following terms including “burning mouth syndrome”, “therapy”, and “treatment” were used for search in the databases. A wide range of articles about the therapeutic approach of BMS was searched and reviewed. Pharmacological and non-pharmacological approaches have been used for BMS management. Pharmacological treatments are including Capsaicin, Clonazepam, Low-dose aripiprazole, Alpha-lipoic acid, Duloxetine, Amitriptyline, Gabapentin, and Pregabalin, and ultra-micronized palmitoylethanolamide. Non-pharmacological therapies for BMS are cognitive therapy, Electroconvulsive therapy, Laser therapy, Acupuncture and auriculotherapy, Transcranial Magnetic Stimulation (rTMS), Salivary Mechanical Stimulation, and Botulinum Toxin. A detailed assessment of the etiology and pathophysiology of BMS, and having information about novel therapeutic interventions are essential for the management of BMS.

Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors

2003 ◽  
Vol 70 ◽  
pp. 201-212 ◽  
Author(s):  
Hideaki Nagase ◽  
Keith Brew
Keyword(s):  
Three Dimensional ◽  
Therapeutic Interventions ◽  
Tissue Inhibitors Of Metalloproteinases ◽  
Structural Basis ◽  
Structural Elements ◽  
Ridge Structure ◽  
Extracellular Matrix Components ◽  
Metalloproteinase Inhibitors ◽  
The Matrix ◽  
A Disintegrin And Metalloproteinase

The tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of the matrix metalloproteinases (MMPs), enzymes that play central roles in the degradation of extracellular matrix components. The balance between MMPs and TIMPs is important in the maintenance of tissues, and its disruption affects tissue homoeostasis. Four related TIMPs (TIMP-1 to TIMP-4) can each form a complex with MMPs in a 1:1 stoichiometry with high affinity, but their inhibitory activities towards different MMPs are not particularly selective. The three-dimensional structures of TIMP-MMP complexes reveal that TIMPs have an extended ridge structure that slots into the active site of MMPs. Mutation of three separate residues in the ridge, at positions 2, 4 and 68 in the amino acid sequence of the N-terminal inhibitory domain of TIMP-1 (N-TIMP-1), separately and in combination has produced N-TIMP-1 variants with higher binding affinity and specificity for individual MMPs. TIMP-3 is unique in that it inhibits not only MMPs, but also several ADAM (a disintegrin and metalloproteinase) and ADAMTS (ADAM with thrombospondin motifs) metalloproteinases. Inhibition of the latter groups of metalloproteinases, as exemplified with ADAMTS-4 (aggrecanase 1), requires additional structural elements in TIMP-3 that have not yet been identified. Knowledge of the structural basis of the inhibitory action of TIMPs will facilitate the design of selective TIMP variants for investigating the biological roles of specific MMPs and for developing therapeutic interventions for MMP-associated diseases.

Inflammageing in the cardiovascular system: mechanisms, emerging targets, and novel therapeutic strategies

2020 ◽  
Vol 134 (17) ◽  
pp. 2243-2262
Author(s):  
Danlin Liu ◽  
Gavin Richardson ◽  
Fehmi M. Benli ◽  
Catherine Park ◽  
João V. de Souza ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Cardiovascular System ◽  
Nlrp3 Inflammasome ◽  
Molecular Mechanisms ◽  
Molecular Targets ◽  
Therapeutic Interventions ◽  
Low Grade ◽  
Cardiovascular Research ◽  
Inflammatory Processes ◽  
Ach Receptors

Abstract In the elderly population, pathological inflammation has been associated with ageing-associated diseases. The term ‘inflammageing’, which was used for the first time by Franceschi and co-workers in 2000, is associated with the chronic, low-grade, subclinical inflammatory processes coupled to biological ageing. The source of these inflammatory processes is debated. The senescence-associated secretory phenotype (SASP) has been proposed as the main origin of inflammageing. The SASP is characterised by the release of inflammatory cytokines, elevated activation of the NLRP3 inflammasome, altered regulation of acetylcholine (ACh) nicotinic receptors, and abnormal NAD+ metabolism. Therefore, SASP may be ‘druggable’ by small molecule therapeutics targeting those emerging molecular targets. It has been shown that inflammageing is a hallmark of various cardiovascular diseases, including atherosclerosis, hypertension, and adverse cardiac remodelling. Therefore, the pathomechanism involving SASP activation via the NLRP3 inflammasome; modulation of NLRP3 via α7 nicotinic ACh receptors; and modulation by senolytics targeting other proteins have gained a lot of interest within cardiovascular research and drug development communities. In this review, which offers a unique view from both clinical and preclinical target-based drug discovery perspectives, we have focused on cardiovascular inflammageing and its molecular mechanisms. We have outlined the mechanistic links between inflammageing, SASP, interleukin (IL)-1β, NLRP3 inflammasome, nicotinic ACh receptors, and molecular targets of senolytic drugs in the context of cardiovascular diseases. We have addressed the ‘druggability’ of NLRP3 and nicotinic α7 receptors by small molecules, as these proteins represent novel and exciting targets for therapeutic interventions targeting inflammageing in the cardiovascular system and beyond.

Sign in / Sign up

Export Citation Format

Share Document